Cardiome Announces The Addition Of Dr. Steen Juul-Möller As Medical Director, Europe

Cardiome Announces The Addition Of Dr. Steen Juul-Möller As Medical Director, 
VANCOUVER, March 28, 2013 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: 
COM) today announces the addition of Steen Juul-Möller, M.D., Ph.D./DMSc., 
FESC to Cardiome's management team as Medical Director, Europe. In his 
capacity of Medical Director, Dr. Juul-Möller will oversee Cardiome's 
clinical and medical affairs activities. 
Dr. Juul-Möller has held his clinical position at the Malmö University 
Hospital (now Skåne University Hospital) since 1980. He is a strong proponent 
for the rapid cardioversion of patients with recent onset atrial fibrillation 
(AF). Dr. Juul-Möller was responsible for changing his hospital's emergency 
room AF management protocol and developed an AF fast-track treatment system 
where patients were safely and rapidly cardioverted resulting in both patient 
and economic benefits. Vernakalant was regularly used in the atrial 
fibrillation fast-track protocol. Since BRINAVESS™ was available in 
Sweden,clinicians at Skåne University Hospital haveused it to cardiovert 
over 250 recent onset atrial fibrillation patients to normal sinus rhythm 
achieving successful cardioversion in 70% to 80% of patients, which is almost 
50% higher than what was achieved in clinical trials. He has also served on 
the Steering Committee of both the ACT I and ACT III pivotal Phase 3 trials 
for vernakalant. 
"We are thrilled to have Dr. Juul-Möller join Cardiome's medical team," said 
Bill Hunter, M.D., Cardiome's President and CEO. "Sharing his BRINAVESS™ 
experience with other clinicians and decision makers such as the 
identification of patients who would best respond to BRINAVESS™ and the 
economic benefits his hospital has gained after implementing a fast-track AF 
protocol will be key as Cardiome assumes BRINAVESS™ commercialization 
In addition to clinical practice, he has concentrated his research activities 
on clinical cardiology. He successfully ran a large clinical project involving 
94 centers in Sweden, the results of which were singularly responsible for the 
1997 FDA recommendation of aspirin treatment for primary prevention of 
myocardial infarction in patients with stable angina (published in Lancet 
For the last 10 years, Dr. Juul-Möller has directed his research towards 
arrhythmias and international drug development including Phase 2 through to 
Phase 4 clinical studies, frequently utilizing the state-of-the-art Laboratory 
for Ambulatory ECG Monitoring. He has had an instrumental role in creating the 
first Scandinavian Syncope Center, located in Malmö and developing a 
fast-track atrial fibrillation treatment program at his hospital. 
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the 
discovery, development and commercialization of new therapies that will 
improve the health of patients around the world. Cardiome has one marketed 
product, BRINAVESS™ (vernakalant IV), approved in Europe and other 
territories for the rapid conversion of recent onset atrial fibrillation to 
sinus rhythm in adults. 
Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock 
Exchange (COM). For more information, please visit our web site at 
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements 
within the meaning of the Private Securities Litigation Reform Act of 1995 or 
forward-looking information under applicable Canadian securities legislation 
that may not be based on historical fact, including without limitation 
statements containing the words "believe", "may", "plan", "will", "estimate", 
"continue", "anticipate", "intend", "expect" and similar expressions. 
Forward- looking statements may involve, but are not limited to, comments with 
respect to our objectives and priorities for the remainder of 2013 and beyond, 
our strategies or future actions, our targets, expectations for our financial 
condition and the results of, or outlook for, our operations, research and 
development and product and drug development. Such forward-looking statements 
involve known and unknown risks, uncertainties and other factors that may 
cause the actual results, events or developments to be materially different 
from any future results, events or developments expressed or implied by such 
forward-looking statements. Many such known risks, uncertainties and other 
factors are taken into account as part of our assumptions underlying these 
forward-looking statements and include, among others, the following: general 
economic and business conditions in the United States, Canada, Europe, and the 
other regions in which we operate; market demand; technological changes that 
could impact our existing products or our ability to develop and commercialize 
future products; competition; existing governmental legislation and 
regulations and changes in, or the failure to comply with, governmental 
legislation and regulations; availability of financial reimbursement coverage 
from governmental and third-party payers for products and related treatments; 
adverse results or unexpected delays in pre-clinical and clinical product 
development processes; adverse findings related to the safety and/or efficacy 
of our products or products; decisions, and the timing of decisions, made by 
health regulatory agencies regarding approval of our technology and products; 
the requirement for substantial funding to expand commercialization 
activities; and any other factors that may affect our performance. In 
addition, our business is subject to certain operating risks that may cause 
any results expressed or implied by the forward-looking statements in this 
presentation to differ materially from our actual results. These operating 
risks include: our ability to attract and retain qualified personnel; our 
ability to successfully complete pre-clinical and clinical development of our 
products; changes in our business strategy or development plans; intellectual 
property matters, including the unenforceability or loss of patent protection 
resulting from third-party challenges to our patents; market acceptance of our 
technology and products; our ability to successfully manufacture, market and 
sell our products; the availability of capital to finance our activities; and 
any other factors described in detail in our filings with the Securities and 
Exchange Commission available at and the Canadian securities 
regulatory authorities at Given these risks, uncertainties and 
factors, you are cautioned not to place undue reliance on such forward-looking 
statements and information, which are qualified in their entirety by this 
cautionary statement. All forward-looking statements and information made 
herein are based on our current expectations and we undertake no obligation to 
revise or update such forward-looking statements and information to reflect 
subsequent events or circumstances, except as required by law. 
Cardiome Investor Relations (604) 676-6993 or Toll Free: 1-800-330-9928 
SOURCE: Cardiome Pharma Corp. 
To view this news release in HTML formatting, please use the following URL: 
CO: Cardiome Pharma Corp.
ST: British Columbia
NI: MTC 2575 WNEWS  
-0- Mar/28/2013 11:15 GMT
Press spacebar to pause and continue. Press esc to stop.